HCP
66
8
RIG
60
2
TGT
22
2
PBI
69
4
KEY
46
3
PEP
48
6
SIG
52
3
BSX
67
-3
HST
49
-9
NEE
50
-5
BBY
46
10
PSX
47
2
EMN
60
4
FTI
81
5
AVY
53
3
HCA
44
-2
FITB
63
3
NAVI
52
5
USB
55
-6
ORCL
65
-2
HCP
66
8
RIG
60
2
TGT
22
2
PBI
69
4
KEY
46
3
PEP
48
6
SIG
52
3
BSX
67
-3
HST
49
-9
NEE
50
-5
BBY
46
10
PSX
47
2
EMN
60
4
FTI
81
5
AVY
53
3
HCA
44
-2
FITB
63
3
NAVI
52
5
USB
55
-6
ORCL
65
-2
Financhill
Back

Cellectis SA 10K Form

Buy
57

CLLS
Cellectis SA

Last Price:
1.88
Seasonality Move:
2.08%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CLLS News And Ratings

See the #1 stock for the next 7 days that we like better than CLLS

CLLS Financial Statistics

Sales & Book Value

Annual Sales: $755K
Cash Flow: $-6.63M
Price / Cash Flow: 2.78
Annual Sales: $1.29
Price / Book: 1.45

Profitability

EPS (TTM): -1.34000
Net Income (TTM): $-84.48M
Gross Margin: $18K
Return on Equity: -79.78%
Return on Assets: -24.83%

Cellectis SA Earnings Forecast

Key Cellectis SA Financial Ratios

  • The Gross Profit Margin over the past 17 years for CLLS is 2.38%.
  • The Selling, General & Administrative Expenses for CLLS have been equal to 2,226.75% of Gross Profit Margin.
  • The Research & Development expenses have been 11,608.74% of Revenue.
  • The Interest Expense is -5.25% of Operating Income.
  • The Net Earning history of CLLS is -13,385.30% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Cellectis SA Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CLLS
CUSIP: 15117K
Website: cellectis.com

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 1.78
Quick Ratio: 1.74

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CLLS Technical Analysis vs Fundamental Analysis

Buy
57
Cellectis SA (CLLS) is a Buy

Is Cellectis SA a Buy or a Sell?

  • Cellectis SA stock is rated a Buy
    The current Cellectis SA [CLLS] share price is $1.87. The Score for CLLS is 57, which is 14% above its historic median score of 50, and infers lower risk than normal.